摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[4-(2-morpholin-4-yl-5,6,7,8-tetrahydroquinazolin-4-ylamino)phenyl]cyclobutanecarboxylic acid | 1215017-69-8

中文名称
——
中文别名
——
英文名称
1-[4-(2-morpholin-4-yl-5,6,7,8-tetrahydroquinazolin-4-ylamino)phenyl]cyclobutanecarboxylic acid
英文别名
1-[4-[(2-Morpholin-4-yl-5,6,7,8-tetrahydroquinazolin-4-yl)amino]phenyl]cyclobutane-1-carboxylic acid
1-[4-(2-morpholin-4-yl-5,6,7,8-tetrahydroquinazolin-4-ylamino)phenyl]cyclobutanecarboxylic acid化学式
CAS
1215017-69-8
化学式
C23H28N4O3
mdl
——
分子量
408.5
InChiKey
RNTPNICBJWQNGO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    30
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    87.6
  • 氢给体数:
    2
  • 氢受体数:
    7

文献信息

  • Novel Biccyclic Compounds As GATA Modulators
    申请人:De Dibyendu
    公开号:US20100144731A1
    公开(公告)日:2010-06-10
    Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.
    提供了新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐,以及新型双环化合物的立体异构体的药用可接受盐。此外,还提供了形成新型双环化合物、立体异构体和/或新型双环化合物的药用可接受盐,以及新型双环化合物的立体异构体的药用可接受盐的方法。
  • US7989463B2
    申请人:——
    公开号:US7989463B2
    公开(公告)日:2011-08-02
  • [EN] NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS<br/>[FR] NOUVEAUX COMPOSÉS BICYCLIQUES COMME MODULATEURS DE GATA
    申请人:REDDYS LAB LTD DR
    公开号:WO2010028174A1
    公开(公告)日:2010-03-11
    Novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided. Additionally, methods of forming novel bicyclic compounds, stereoisomers, and/or pharmaceutically acceptable salts of the novel bicyclic compounds, and/or pharmaceutically acceptable salts of the stereoisomers of the novel bicyclic compounds are provided.
查看更多